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To elucidate the association between medical proce-
dures and sporadic Creutzfeldt-Jakob disease (sCJD), we 
analyzed medical procedures (any surgical procedure, neu-
rosurgery, ophthalmic surgery, and blood transfusion) for 
patients registered by the CJD Surveillance Committee in 
Japan during 1999–2008. We conducted an age-stratifi ed 
case–control study with 753 sCJD patients and 210 con-
trols and a study of patients who underwent neurosurgical 
or ophthalmic surgical procedures at the same hospital. Al-
though the control group was relatively small, no evidence 
was found that prion disease was transmitted through the 
investigated medical procedures before onset of sCJD. After 
onset of sCJD, 4.5% of the sCJD patients underwent opera-
tions, including neurosurgical for 0.8% and ophthalmic for 
1.9%; no special precautions against transmission of prion 
diseases were taken. Fortunately, we have not identifi ed pa-
tients with prion disease attributed to these operations. Our 
fi ndings indicate that surgical procedures or blood transfu-
sion had little effect on the incidence of sCJD.
Prion disease is characterized by spongiform change and abnormal prion protein deposition in the brain and is 
transmissible under certain situations. Human prion disease 
is divided into 3 categories: genetic prion diseases with 
mutations of the prion protein (PrP) gene; prion diseases 
acquired by transmission of the prion through exposure to 
contaminated materials, including iatrogenic transmission; 
and sporadic Creutzfeldt-Jakob disease (sCJD) with no PrP 
mutation or evidence of exposure to prion. To date, >400 
patients with iatrogenic CJD, who received prions through 
contaminated neurosurgical instruments, intracerebral elec-
troencephalographic electrodes, human pituitary hormone, 
corneal transplants, or dura mater grafts, have been report-
ed (1). Furthermore, some case–control studies reported 
that medical procedures were possible risk factors for sCJD 
(2–6). However, other studies did not demonstrate any sig-
nifi cant association between medical procedures and sCJD 
(7–10).
After a results of a case–control study that found an 
association between CJD and medical procedures was 
reported from Japan in 1982 (2), 132 patients with dura 
mater graft–associated CJD (dCJD) have been found in Ja-
pan (11,12); however, no recent studies have investigated 
medical procedures as a risk for acquiring sCJD. In Japan, 
66 (8.6%) of 766 patients with prion diseases had iatro-
genic cases that were all dCJD (12), and the outbreak of 
iatrogenic CJD required a new study about the association 
between sCJD and medical procedures in Japan. Here we 
analyzed the role of medical procedures in cases of sCJD 
by using relevant data from CJD surveillance in Japan.
Methods
Patients
We investigated 1,339 patients with suspected prion 
diseases who had been registered by the CJD Surveil-
lance Committee in Japan from April 1999 through Febru-
ary 2008. The surveillance system was initiated in April 
1999, and each patient was prospectively assessed with a 
surveillance protocol that assembled information about life 
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history; previous medical history, including the history of 
surgical treatment and blood transfusion; clinical history; 
laboratory data; and results of molecular genetic and patho-
logic examinations. Information on patients with suspected 
prion diseases were obtained through 1) the application for 
registration with the Japanese Intractable Diseases Informa-
tion Center (www.nanbyou.or.jp/english/nan_kenkyu_45.
htm) by each patient’s family, 2) the law on infectious dis-
eases, or 3) request for genetic or cerebrospinal fl uid analy-
ses sent to members of the CJD Surveillance Committee by 
the physicians. In Japan, 123 diseases have been defi ned 
as intractable disease, and for 45 of them, including prion 
diseases, patients receive additional economic support for 
medical costs. Furthermore, medical doctors must report 
patients suspected of having prion disease to the local pub-
lic health department within 7 days after the diagnosis, ac-
cording to the law on infectious diseases (which has been 
enforced since April 1999 in Japan to monitor some spe-
cifi c infectious diseases). After written consent approved 
by the Institutional Ethics Committee was obtained from 
each patient’s family, members of the CJD Surveillance 
Committee directly examined the patient and collected data 
from the clinical records. For each patient with a history 
of surgery, we collected information about the underlying 
disease from the patient’s family, including the date and 
hospital in which the operation was performed. For each 
patient with a history of blood transfusion, we collected in-
formation about the date of blood transfusion. Most infor-
mation was collected by interviewing the patient’s family 
members.
On the basis of discussions by the CJD Surveillance 
Committee, we confi rmed or denied the diagnosis of prion 
disease in each case. In patients with a confi rmed diag-
nosis of prion disease, we classifi ed prion diseases into 
4 categories: sCJD, acquired prion disease, genetic prion 
disease, and unclassifi ed prion disease. sCJD was diag-
nosed according to the revised classical criteria established 
by Masters et al. (13): defi nite CJD (neuropathologically 
confi rmed spongiform encephalopathy or abnormal prion 
protein deposition in the brain); and probable CJD (neu-
ropathologically unconfi rmed cases showing progressive 
dementia, periodic sharp-wave complexes on electro-
encephalogram, and at least 2 of the following features: 
myoclonus, pyramidal signs/extrapyramidal signs, cer-
ebellar signs or visual symptoms, and akinetic mutism). 
Acquired prion diseases included iatrogenic CJD, in which 
the criteria for sCJD were applied for a diagnosis with a 
history of iatrogenic exposure, and variant CJD, in which 
the diagnosis was based on the World Health Organization 
(WHO) 2001 criteria (14). Regarding the accuracy of the 
diagnosis of genetic prion diseases, pathologically verifi ed 
cases were defi ned as “defi nite,” and cases demonstrating 
mutations in the PrP gene and neuropsychiatric manifes-
tations compatible with prion diseases were defi ned as 
“probable.” We selected patients with defi nite or probable 
sCJD for analysis.
Patients who did not receive a diagnosis of prion dis-
eases were classifi ed into 3 categories: prion diseases defi -
nitely denied; prion diseases probably denied; and diag-
nosis unclear. “Prion diseases defi nitely denied” indicated 
patients whose conditions were defi nitively diagnosed as 
diseases other than prion diseases, and “prion diseases 
probably denied” indicated patients for whom the diagnosis 
of prion diseases was clearly unlikely due to the improving 
or nonprogressive disease course or for other reasons, al-
though a defi nitive diagnosis of another disease was not es-
tablished. Because patients with “prion diseases defi nitely 
denied” or “prion disease probably denied” had no or little 
possibility of prion disease, we selected these cases as the 
controls in our case–control study.
Surgical Procedures and Blood 
Transfusions before Onset of sCJD
To estimate the risk for sCJD through past surgery or 
blood transfusion, we performed a case–control study. Op-
erations were divided into the following categories: neuro-
surgery, ophthalmic surgery, and surgery other than neu-
rosurgery or ophthalmic surgery (other surgery), because 
neurosurgery or ophthalmic surgery for those with prion 
diseases are categorized in the guidelines of the CJD Inci-
dent Panel in the United Kingdom as high- or medium-risk 
procedures for transmission of infective PrP (15). In these 
guidelines, procedures involving the olfactory epithelium 
are also categorized as medium risk (15). However, the 
number of persons who underwent the operation possibly 
involving the olfactory epithelium is too small to be esti-
mated by statistical analysis (2 sCJD patients and 2 controls 
underwent surgery for sinusitis), and we categorized these 
operations as other surgery. Neurosurgery included opera-
tions on the brain, cerebral blood vessels, and spinal cord. 
Ophthalmic surgery included all operations involving the 
eyeball and optic nerve. Other surgery included all surgical 
procedures other than neurosurgery and ophthalmic sur-
gery. Furthermore, the committee performed a detailed in-
vestigation of sCJD patients who underwent neurosurgery 
or ophthalmic surgery at a hospital where other patients 
with any type of prion disease had ever undergone neuro-
surgery or ophthalmic surgery.
Surgical Procedures after Onset of sCJD 
We analyzed sCJD patients who underwent surgical 
procedures after the onset of sCJD because such proce-
dures might cause secondary transmission of the disease 
through contaminated instruments. In particular, for neuro-
surgery and ophthalmic surgery, we investigated the reason 
for the operation, interval between the operation and onset 
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of sCJD symptoms, age at onset of sCJD, and symptoms at 
onset of sCJD.
Statistical Analyses 
Between the sCJD and control groups, age at onset 
was compared by Student t test, and medical procedures 
before the onset of diseases were compared by Fisher ex-
act test. The case–control study of surgical procedures 
and blood transfusions before the onset of diseases was 
estimated by logistic-regression analysis. Because age 
at onset was different among sCJD patients (mean ± 
SD, 67.7 ± 9.5 years) and controls (59.3 ± 16.6 years) 
(p<0.0001), we divided the sCJD patients and controls 
into 3 categories according to age at disease onset; 31–50 
years, 51–70 years, and >71 years. We performed a single 
regression analysis for any operation, neurosurgical pro-
cedure, ophthalmic surgical procedure, other operation, 
and blood transfusion in each age group. The strength of 
association between sCJD and putative risk factors was 
assessed by the odds ratios and 95% confi dence intervals. 
Signifi cance was defi ned as p<0.05. Statistical analyses 
were performed by using StatView J-7.5 (Abacus Con-
cepts, Berkeley, CA, USA).
Results
A total of 990 patients received a diagnosis of defi -
nite or probable prion disease. Summary of the characteris-
tics of patients with prion diseases is shown in Table 1, in 
which 760 patients with sCJD are included. There were 221 
patients with “prion disease defi nitely denied” and “prion 
disease probably denied.” Seven sCJD patients and 11 con-
trol patients were excluded from the case–control study be-
cause information on medical history was not suffi cient for 
analysis. Diagnoses of the 210 control patients is shown in 
Table 2.
Medical Procedures before Onset of sCJD 
Frequencies of medical procedures before the onset 
of sCJD in sCJD patients and in controls are compared in 
Table 3. For both the sCJD and control groups, ≈50% had a 
history of surgery, and ≈10% had received a blood transfu-
sion. No signifi cant differences were found between them 
in frequency of any surgery, neurosurgery, ophthalmic sur-
gery, other surgery, or blood transfusion (Table 3). In the 
logistic-regression analysis, no signifi cant risk was associ-
ated with any medical procedures investigated in this study 
(Table 4).
Five sCJD patients had a history of neurosurgery or 
ophthalmic surgery at hospitals where neurosurgery or oph-
thalmic surgery had been performed on patients in whom 
prion disease later developed (Table 5); intervals between 
operations at the same hospitals were >3 years (Table 5).
Surgical Procedures after Onset of sCJD 
Except for 2 patients suspected of having prion dis-
ease, who had undergone brain biopsy with disposable 
instruments, 34 (4.5%) of 760 sCJD patients underwent 
some type of surgical procedure before the diagnosis of 
prion disease, including neurosurgery in 6 (0.8%), ophthal-
mic surgery in 14 (1.8%), and other surgery in 16 (2.1%). 
The 6 case-patients who underwent neurosurgery had these 
operations within 3 months after sCJD onset: procedures 
performed for subdural hematoma (n = 3), aneurysm (n = 
2), and menigioma (n = 1) (Table 6). All 14 case-patients 
who underwent ophthalmic surgery underwent operations 
for cataracts, and 7 of these patients had had visual distur-
bance as an initial symptom of sCJD (Table 7). Among 5 
patients for whom information on the effects of ophthalmic 
surgery could be obtained, 2 had some improvement of vi-
sual symptoms after surgery, but the other 3 patients had 
no improvement. Although both cataracts and sCJD could 
contribute to the visual symptoms, sCJD would contrib-
ute to visual symptoms in patients who had no effects of 
ophthalmic surgery. We have obtained information about 
instrument cleaning and sterilization procedures for 3 of 5 
patients who underwent neurosurgery and for 5 of 14 pa-
tients who underwent ophthalmic surgery after the onset 
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Table 1. Characteristics of patients with definite or probable prion 
disease, Japan, 1999–2008* 
Type of prion disease No. (%) patients 
Sporadic CJD 760 (76.8) 
Genetic prion diseases 167 (16.9) 
Acquired prion diseases† 62 (6.3) 
Unclassified CJD 1 (0.1) 
Total 990
*CJD, Creutzfeldt-Jakob disease. 
†Acquired prion diseases included 61 cases of dura mater CJD and 1 
case of variant CJD. 
Table 2. Diagnoses for 210 controls in case–control study of 


















*sCJD, sporadic Creutzfeldt-Jakob disease. 
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of sCJD. All surgeons reused some of the surgical instru-
ments, but according to the WHO guidelines (16), the ster-
ilization methods of the instruments were not appropriate 
for eliminating infectious PrP, including the use of ethylene 
oxide gas or incomplete autoclaving.
Discussion
In this case–control study, we found no evidence of 
increased sCJD risk associated with patient’s history of 
surgical procedures or blood transfusions. In the previ-
ous case–control study and in our study, receipt of a blood 
transfusion was not shown to be a signifi cant risk for CJD 
(2–10). However, whether surgical procedures contribute 
to the risk for sCJD has been controversial. Our results, in 
which any operation was not a signifi cant risk for sCJD, 
were consistent with results of 2 previous large case–con-
trol studies (8,9) and a reanalysis of results of 3 case–con-
trol studies (10). Even in the studies with positive results, 
some different results were provided when the surgical pro-
cedures were categorized by affected organ. One previous 
case–control study indicated signifi cant risk for sCJD after 
neurosurgical procedures (3), but no signifi cant risk was 
shown in other studies (5,6,8–10). Ophthalmic surgery was 
reported as causing signifi cant risk for sCJD in a case–con-
trol study in Australia (4) but not in other studies (5,6–10). 
In a recent study in the United Kingdom (6), the increased 
risk associated with having undergone surgical procedures 
was restricted to the category “other surgery,” which in-
cluded such procedures as sutures to skin, and the asso-
ciation largely disappeared when the whole of the other-
surgery category was excluded. These different results may 
show little possibility for transmission of infectious PrP 
through surgical procedures, although we cannot exclude 
the possibility that such transmission occurs occasionally 
because iatrogenic CJD exists.
The confl icting results in case–control studies, includ-
ing ours, may be explained by differences in the area, race, 
period in which studies were performed, number of pa-
tients, and methods as discussed below. Our study, which 
attempted to determine when medical procedures were as-
sociated with an increased risk for sCJD, had the largest 
number of sCJD patients in case–control studies to date. 
The relatively small number of controls is a potential limi-
tation. In case–control studies, methods of obtaining data 
from controls should be the same as those from patients. 
In our study, patients in the groups “prion diseases defi -
nitely denied” or “prion diseases probably denied” in our 
CJD surveillance, who had no or little possibility of having 
prion disease, were used as the controls. Therefore, data 
from controls could be collected at the same level of pre-
cision as those from the sCJD cases. Because the ages of 
the sCJD patients and controls were signifi cantly different, 
age-stratifi ed analysis was required in our study. A recent 
study reported that some methodologic differences might 
partially explain confl icting data regarding the association 
between surgical procedures and CJD (17). The report sug-
gested that the use of controls from the community would 
be preferable to using those from the hospital because com-
munity-based controls are often more representative and 
would result in a more valid comparison (17). Furthermore, 
268 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 2, February 2009
Table 3. Medical procedures before disease onset, case–control 
study of sCJD, Japan, 1999–2008* 
Medical procedures 
sCJD case-patients, 
no. (%), n = 753  
Controls,
no. (%), n = 210 
Surgery 372 (49.4) 104 (49.5) 
 Neurologic 25 (3.3) 13 (6.2) 
 Ophthalmic  42 (5.6) 11 (5.2) 
 Other 337 (44.8) 89 (42.4) 
Blood transfusion 78 (10.4) 20 (9.5) 
*sCJD, sporadic Creutzfeldt-Jakob disease. p values were not significant. 
Table 4. Medical procedures and risk for sCJD, by age at disease onset, Japan, 1999–2008* 
Age
range, y Data category 
Total no. 
patients Any surgery Neurosurgery 
Ophthalmic
surgery Other surgery 
Blood
transfusion
sCJD 32 50.0% 6.3% 6.3% 40.6% 3.1%
Control 37 45.9% 10.8% 2.7% 37.8% 5.4%
OR 1.66 0.38 2.15 0.78 0.64
95% CI 0.04–74.09 0.02–6.64 0.05–101.51 0.02 – 33.39 0.05–9.09
31–50
p value 0.79 0.50 0.70 0.90 0.74
sCJD 414 43.7% 1.7% 2.2% 41.8% 9.4%
Control 97 46.4% 5.2% 3.1% 40.2% 11.3%
OR 0.18 0.69 2.71 5.57 0.84
95% CI 0.02–1.73 0.13–3.62 0.24–30.38 0.62–50.05 0.40–1.77
51–70
p value 0.14 0.66 0.42 0.13 0.64
sCJD 317 57.0% 5.2% 10.1% 49.2% 12.4%
Control 60 65.0% 6.7% 10.0% 56.7% 11.7%
OR 0.81 0.76 1.15 0.83 1.27
95% CI 0.15–4.37 0.15–3.80 0.38–3.48 0.17–4.02 0.52–3.10
>71
p value 0.80 0.74 0.81 0.82 0.60
*sCJD, sporadic Creutzfeldt-Jakob disease; OR, odds ratio; CI, confidence interval. 
Medical Procedures and sCJD, Japan
using proxy informants for controls may be advisable for 
the purpose of comparability with case-patients, although 
this practice does not necessarily offset biases in data as-
certainment (17). In our case–control study, we used proxy 
informants for controls who were recruited from hospitals 
under the same condition as the sCJD case-patients.
Regarding the 5 sCJD patients with a history of neu-
rosurgical or ophthalmic surgical procedures at hospitals 
where other patients with prion disease had previously un-
dergone such procedures, we consider that the possibility 
of transmission through these procedures was extremely 
limited because the intervals between procedures and the 
acquisition of sCJD had been >3 years for all patients. Ac-
cording to the Incident Panel in the United Kingdom, most 
instruments that have gone through 10 cycles of use and 
decontamination are unlikely to pose a substantial risk (15). 
We assume that all instruments had gone through >10 cy-
cles of use during the 3-year interval, and almost no infec-
tivity remained on the instruments. In Japan, a large num-
ber of dCJD patients have been recognized with no other 
types of iatrogenic CJD (11,12); this study confi rmed that 
no surgically transmitted cases occurred among patients 
with sCJD.
It is noteworthy that 4.5% of the sCJD patients under-
went some types of surgical procedures after the disease 
onset, including neurosurgical (0.8%) and ophthalmic pro-
cedures (1.8%). Through surgical instruments, neurosurgi-
cal operations may transmit high infectivity from the brain 
tissues of sCJD patients, and ophthalmic operations may 
transmit moderate infectivity of the eye tissues in cases 
of cataracts (15). In this study, all these neurosurgical and 
ophthalmic procedures were performed without suspicion 
of prion diseases or special precautions to reduce the risk 
for secondary transmission of prion infection through the 
instruments. These fi ndings suggest that delayed diag-
nosis of sCJD would be linked to increased risk for sec-
ondary transmission of prion diseases through surgical 
instruments. In neurosurgical procedures, the symptoms 
of sCJD were misdiagnosed as those of other neurologic 
diseases, and operations were performed near the time of 
disease onset. In terms of ophthalmic surgery, all patients 
underwent operations for cataracts, and 7 (50%) of 14 
patients had visual disturbances as an initial symptom of 
sCJD. These data are similar to those in a report from the 
United Kingdom (18). Visual disturbances might prompt 
ophthalmic surgery. More seriously, 3 patients underwent 
operations >8 months after sCJD onset. In this study, all 
surgeons who provided information reused the surgical in-
struments with incomplete sterilization, and the potential 
for infection was the same as in our previous study of oph-
thalmic surgery (19).
Neurosurgeons and ophthalmologists should become 
better informed about prion diseases and the necessity of 
using disposable instruments whenever possible. Further-
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Table 5. Characteristics of 5 sCJD patients who underwent neurosurgery or ophthalmic surgery at hospitals where other patients with 
prion diseases had previously undergone neurosurgery or ophthalmic surgery, Japan, 1999–2008* 
Patient Type of CJD Onset of CJD Date of surgery Reason for surgery 
1 sCJD 2003 Aug 1991 Aug Subarachinoid hemorrhage 
dCJD 2001 May 1976 Spinal cord tumor 
1986 Aug Spinal cord tumor 
2 sCJD 2002 Feb 1994 Sep Subdural hematoma 
1997 Sep Cataract
dCJD 1998 Jan 1987 Jan Meningioma
3 sCJD 2001 Jan 1989 Apr Subarachinoid hemorrhage 
dCJD 1995 Jul 1980 Jul Aneurysm 
4 sCJD 2001 Jul 1999 Spinal cord lesion (details unknown) 
dCJD 2001 Aug 1978 Sep Astrocytoma 
5 sCJD 2002 May 2002 Apr Cataract
sCJD 2002 May 1997 Aug Cataract
1999 Jan Cataract
*CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; dCJD, Creutzfeldt-Jakob disease associated with cadaveric dura mater graft.
Table 6. Data for sCJD patients who underwent neurosurgery after onset of sCJD symptoms, Japan, 1999–2008* 
Patient
no. Reason for surgery 
Interval between onset of sCJD symptoms 
and surgery, mo Age at onset of sCJD, y Symptom at onset of sCJD
1 Subdural hematoma 0 71 Dementia
2 Subdural hematoma 0 77 Apathy 
3 Subdural hematoma 1 57 Dementia
4 Meningioma 1 74 Vertigo
5 Aneurysm 2 46 Dementia
6 Aneurysm 3 67 Vertigo
*sCJD, sporadic Creutzfeldt-Jakob disease. 
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more, a more sensitive method for early diagnosis of sCJD 
is needed because clinical diagnosis is sometimes diffi cult, 
particularly in atypical sCJD cases, such as MM2, MV2, 
VV1, or VV2 types (20–23), according to 6 phenotypes of 
sCJD divided by codon 129 polymorphisms of PrP (methi-
onine/valine) and type of infectious PrP by Western blot-
ting (24). Even neurologists may misdiagnose the initial 
stage of the atypical sCJD cases as being another neurode-
genrative disease such as Alzheimer disease and progres-
sive supranuclear palsy (20). Moreover, patients who have 
undergone surgical procedures with possibly contaminated 
instruments need to undergo a risk assessment with long-
term follow-up after careful ethical consideration. Since 
June 2004, we have identifi ed and monitored all patients 
who underwent neurosurgical procedures with possibly 
contaminated instruments, CJD has developed in none of 
those patients.
In conclusion, we did not demonstrate any evidence of 
increased risk for sCJD associated with a history of surgery 
or blood transfusion in the Japanese surveillance system. 
However, the fact that some patients had surgeries, includ-
ing neurosurgery, even after the onset of sCJD indicates 
that we cannot deny any possibility of transmission of prion 
diseases by medical procedures. Neurosurgeons, ophthal-
mologists, and other surgeons need to focus more attention 
on prion diseases to reduce the iatrogenic risk, as well as re-
alize that prolonged, careful surveillance of prion diseases 
is necessary.
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